embolism

(redirected from Embolic event)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Related to Embolic event: Intracranial embolism
  • noun

Synonyms for embolism

an insertion into a calendar

occlusion of a blood vessel by an embolus (a loose clot or air bubble or other particle)

References in periodicals archive ?
Indications for valve replacement surgery include development of heart failure, embolic events, and hemodynamic instability.
They could have edema in the brain, or retinal detachments, or embolic events to the retinal arteries," Dr.
TM)] offers an unmatched ability to protect against plaque protrusion and prevent embolic events.
Committee votes 9 to 1 to recommend approval of once-daily SAVAYSA for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF)
The company will seek approval for the once-daily oral drug for the treatment of pulmonary embolism and deep vein thrombosis, as preventive treatment for recurrent symptomatic venous thromboembolism, and for the reduction of risk for stroke and systemic embolic events among patients with nonvalvular atrial fibrillation.
Approximately 30 percent of strokes are caused by embolic events originating from diseased carotid arteries.
There were no embryopathies in this group, but in the patients who were not using warfarin, there were 13 valve thromboses (4 fatal) and eight embolic events (two fatal).
Daiichi Sankyo is seeking approval for edoxaban for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF), as well as for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and for the prevention of recurrence of symptomatic venous thromboembolism (VTE).
1] This clinical trial found that the investigational, oral, once-daily direct factor Xa-inhibitor edoxaban met the primary efficacy endpoint of non-inferiority compared to warfarin for the prevention of stroke or systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF).
Clinical problems in noncompaction are usually related to heart failure, arrhythmias and systemic embolic events that led us to begin warfarin treatment.
There is a common misconception that athletes are prone to arrhythmias that could trigger stroke or embolic events, and that the "athlete's heart" itself predisposes arrhythmia.
In Europe, Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF), as well as for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrence of symptomatic venous thromboembolism (VTE).
Anticipating this problem, SMT has spent five years developing and refining a deflection device specifically designed to reduce the chance of stroke and embolic events during TAVI and other structural heart procedures.